|
||||||
 |
||||||
|
|
|
 |
|
          May 9, 2012
May 1, 2012
|
|
Tous les prix sont au moins quinze minutes en retard.
Tous les prix sont au moins |
|
Bioniche Life Sciences Inc. Award of ExcellenceThe Bioniche Life Sciences Inc. Award of Excellence recognizes individuals who contribute significantly to the achievement of the Company’s corporate objectives. Individual nominations for this award are brought forward to the Company’s Executive Management Team for consideration. Récipiendaire du Prix d’excellence de cette année (troisième année) : Docteur Brett FinlayPrix présenté lors de l’ouverture officielle du Centre de fabrication des vaccins, destiné à la santé animale et à la salubrité des aliments - en avril 2011
Docteur Dragan Rogan, agent scientifique en chef et vétérinaire chez Bioniche Life Sciences Inc. (à droite) remettant au docteur Brett Finlay le Prix d’excellence de Bioniche Life Sciences Inc. de cette année (troisième année), lors de l’ouverture officielle du Centre de fabrication des vaccins destiné à la santé animale et à la salubrité des aliments, le 29 avril 2011. Le docteur Brett Finlay est professeur au Michael Smith Laboratories et dans les départements de biochimie et biochimie moléculaire et de microbiologie et immunologie de la University of British Columbia (UBC). C’est docteur Finlay qui a fait les découvertes scientifiques d’origine qui ont mené au développement du vaccin. Il effectuait des recherches de base en laboratoire en 1995, lorsqu’il a fait une découverte majeure : la bactérie E. coli O157:H7 secrétait des protéines qui, au contact de la paroi cellulaire intestinale, servaient de récepteurs qui permettaient à la bactérie de se fixer et de coloniser les intestins. Le docteur Finlay a réalisé qu’il pouvait être possible d’immuniser contre les protéines d’ancrage de la bactérie. Au départ, cela lui a paru intéressant à appliquer aux vaccins pour enfants. Puis, il s’est aperçu qu’un vaccin destiné au bétail semblait présenter plus d’intérêt. Il prit contact avec la Vaccine and Infectious Diseases Organization (VIDO) de la University of Saskatchewan pour aider à fabriquer des protéines sécrétées pour immuniser les vaches. L’entreprise Bioniche Life Sciences, par l’intermédiaire du Canadian Bacterial Diseases Network (CBDN), devint le partenaire commercial sur la recommandation du docteur Dragan Rogan, qui à l’époque était vice-président de la recherche en santé animale chez Bioniche. Ce dernier a vu le potentiel du vaccin et sa nécessité. C’est donc grâce au partenariat entre UBC, VIDO, le Alberta Research Council et Bioniche, dirigé par le docteur Rogan et son équipe, que le vaccin a été développé. Les recherches continues du docteur Finlay dans le domaine des pathogènes d’origine alimentaire et des technologies visant à prévenir les maladies chez les êtres humains, ont permis au Canada de rester au premier rang pour ce qui est de la recherche dan le domaine de la salubrité des aliments. Bioniche est fière de travailler en collaboration avec le docteur Finlay et son équipe expérimentée, alors qu’ils effectuent des recherches sur les nouvelles technologies dans ce domaine. Second Award of Excellence Recipient: Dr. Alvaro MoralesPresented at the Annual Meeting of Shareholders – November 9, 2010
Graeme McRae, Chairman, President & CEO of Bioniche (right) presented Dr. Alvaro Morales with the second Bioniche Life Sciences Inc. Award of Excellence at the Annual Meeting of Shareholders in November, 2010. Dr. Alvaro Morales has worked with Bioniche Life Sciences Inc. since its Vetrepharm Animal Health days. He introduced himself to the Company in the 1980s, having come across the Company’s mycobacterial cell wall product for the treatment of canine cancer (Regressin) and inquiring about its potential for the treatment of human bladder cancer. During the 1970s, Dr. Morales hypothesized that infecting the bladder with live BCG (bacillus Calmette-Guérin, a live vaccine developed in the 1920s to prevent Tuberculosis in humans) would provoke an immune system response that would be sufficiently robust to eliminate some bladder tumours. His pioneering work formed the basis for registration of BCG as a bladder cancer therapy. Since its registration, Dr. Morales has been anticipating a new generation of therapy that would have fewer side effects, better tolerability, and be safer for clinicians to handle. Dr. Morales has been the Principal Investigator for the Company’s Phase I and II clinical trials with the Company’s technology , as well as for the first Phase III clinical trial, in which patients with bladder cancer that was refractory (unresponsive) to BCG were treated with the Company’s product. Dr. Morales was the lead author of an article published in the March, 2009 Journal of Urology, a leading, peer reviewed medical journal, in which he summarized the results of the earlier clinical trials with the Company’s technology. He has commented that the tumour response was very encouraging, and that the safety profile was so much better than that seen with the live bacterial product (BCG). Dr. Morales completed his undergraduate training at the Universidad Javeriana in Columbia, his surgical training in Washington, D.C. and Boston, Massachusetts and his urological training at Queen's University. He has been with the Department of Urology since 1972 and was promoted to full Professor in 1982. Dr. Morales stepped down as the Head of Urology in 1997 after 15 dedicated and challenging years in that position. He has, over the years, cultivated much external funding support for the department and carries on numerous clinical drug trials and research projects, on an ongoing basis; primarily in the areas of sexual dysfunction and oncology. He is constantly sought out to be a visiting lecturer all over the world, and also participates in local and international CME events. Dr. Morales has over 260 papers published. His 1976 paper on the use of BCG for the prophylaxis and treatment of superficial bladder cancer has been recognized as one of the most important papers published in the last 100 years on bladder cancer by the Journal of Urology. He sits on several editorial boards, including The International Journal of Impotence Research and as an External Reviewer for the Journal of Urology. He officially retired in 2004, but continues as founding Director of the Centre of Applied Urological Research, for the Department of Urology, a facility that he spearheaded and saw through from concept to reality when it opened in Kingston in 2005. First Award of Excellence Recipient: Dr. Reuben MapletoftPresented at the International Embryo Transfer Society Annual Meeting – January, 2010
Dr. Dragan Rogan, Chief Veterinary Scientific Officer at Bioniche (left) presented Dr. Reuben Mapletoft with the first Bioniche Life Sciences Award of Excellence at the Annual Meeting of the International Embryo Transfer Society in January, 2010. Dr. Reuben Mapletoft is a long-time friend of Bioniche Life Sciences, having worked closely with us for the last decade and having made significant contributions to the development and success of our reproductive products for livestock. He has been honoured by his university peers at the University of Saskatchewan and industry representatives. The government of Saskatchewan awarded him the Order of Merit in 2007 in recognition of his research in reproductive biology and its application in assisted reproductive technologies in cattle, spanning more than 30 years. In 1998, Dr.Mapletoft received an honorary life membership in the Canadian Embryo Transfer Association, and in 2000, he received an honorary life membership and the Distinguished Service Award from the International and Canadian Embryo Transfer Society. In 2003, the University of Saskatchewan honoured him with its Distinguished Researcher Award, and in 2005, an earned a Doctorate. At the Annual Meeting of the International Embryo Transfer Society in Cordoba, Argentina in January, 2010, Dr.Mapletoft was awarded with a newly created corporate award that recognizes individuals who contribute significantly to the achievement of our corporate objectives. The first Bioniche Life Sciences Award of Excellence was presented by Graeme McRae, Chairman President & CEO of Bioniche and Dr. Dragan Rogan, Chief Veterinary Scientific Officer of Bioniche to Dr.Mapletoft, a supporter, contributor, advisor, colleague and friend of our company. In addition to receiving an etched glass award, Bioniche has set up a scholarship in Dr.Mapletoft’s name: The Reuben J. Mapletoft Scholarship for the Study of Bovine Embryo Transfer TechnologyThis annual scholarship is under the supervision of Dr. Gabriel Bo at the Instituto de Reproducción Animal Córdoba (IRAC), Cordoba, Argentina. The scholarship will cover airfare, board and lodging and in depth training for one week. Additional training up to one month may be organized by special arrangement. Candidates must be under 35 years of age, and must submit a short resume, letter of intent outlining their short and long-term goals, and letter of reference to Dr. Dragan Rogan, Chief Veterinary Scientific Officer, Bioniche Animal Health, Belleville, ON, Canada (Dragan.Rogan@Bioniche.com) by January 2nd of each year. Scholarship Form |
|
Droit d'auteur 2004, Bioniche Life Sciences Inc. Tous droits réservés
Mentions légales | Politique de confidentialité